CLEVELAND, April 17, 2019 /PRNewswire/ -- ViewRay, Inc.
(Nasdaq: VRAY) and Device Technologies Australia Pty Ltd (Device
Technologies) announced today a partnership in which Device
Technologies, the largest independent distributor in Australasia,
will market, sell, and support ViewRay's MRIdian MRI-guided
radiation therapy system.
"Device Technologies is the ideal partner to bring the
benefits of the MRIdian System to one of the biggest and best
healthcare markets in the world," said Jim
Alecxih, Chief Commercial Officer at ViewRay. "Device
Technologies has successfully sold, implemented and supported many
other high-tech medical devices, so we're confident given the
growing excitement around MRI-guided radiation therapy, that they
will deliver equally impressive results with MRIdian."
MRIdian provides continuous high-contrast imaging of soft tissue
during radiation therapy treatment to help clinicians position the
patient, track tumor and anatomical motion, and accurately target
treatment. MRIdian also enables on-table adaptive therapy, which
allows clinicians to adapt to changes and movement in the patient's
anatomy in real-time while the patient is being treated, bringing
even greater precision to radiation delivery.
"We're delighted to be including ViewRay's MRIdian in the
portfolio of high-end innovative products for distribution in
Australia and New Zealand," said Mick Trevaskis, CEO of Device Technologies
Australia Pty Ltd. "We always put our patients first, and MRIdian's
simultaneous MRI imaging and radiation therapy provides highly
accurate delivery of radiation to the patient, which helps enable
an optimal clinical outcome in a shorter timeframe."
Device Technologies is dedicated to improving patients' lives
through the supply of leading-edge technology and services to
Australian and New Zealand
hospitals and healthcare professionals. Device Technologies
continues to grow, with more than 250 trusted brands from the
world's most innovative medical companies and 850 highly skilled
staff, making it the largest independent distributor in
Australasia. Customer service and patient care remain critical core
values.
About ViewRay
ViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures and markets
the MRIdian® radiation therapy system. MRIdian is built upon a
proprietary high-definition MR imaging system designed from the
ground up to address the unique challenges and clinical workflow
for advanced radiation oncology. Unlike MR systems used in
diagnostic radiology, MRIdian's high-definition MR was purposely
built to deliver high-precision radiation without unnecessary beam
distortion, and consequently, help to mitigate skin toxicity and
other safety concerns that may otherwise arise when high magnetic
fields interact with radiation beams. ViewRay and MRIdian are
registered trademarks of ViewRay, Inc.
About Device Technologies
Since 1992, Device Technologies Australia Pty Ltd has been
dedicated to improving patients' lives through the supply of
leading edge technology and services to Australian and New Zealand hospitals and healthcare
professionals. Device Technologies continues to grow, with over 250
trusted brands from the world's most innovative medical companies,
and 850 highly skilled staff to make it now the largest independent
distributor in Australasia. Customer service and patient care
remain as their critical core values.
Intended Use: The MRIdian Linac System, with magnetic
resonance imaging capabilities, is intended to provide stereotactic
radiosurgery and precision radiotherapy for lesions, tumors, and
conditions anywhere in the body where radiation treatment is
indicated.
Forward-Looking Statements: This press release contains
forward-looking statements. Statements in this press release that
are not purely historical are forward-looking statements. These
statements are subject to risks and uncertainties that could cause
future results to differ materially from those referenced. Forward
looking statements include, but are not limited to references to
future MRIdian installations, clinical value and outcomes. Given
these uncertainties, the reader is advised not to place any undue
reliance on any forward-looking statements. Additional risk factors
include, among others, the ability to raise the additional funding
needed to continue to pursue ViewRay's business and product
development plans, the inherent uncertainties associated with
developing new products or technologies, competition in the
industry in which ViewRay operates, government and regulatory
uncertainty, including but not limited to obtaining authorizations
to market and new tariffs and trade restrictions, and overall
market conditions. These forward-looking statements are made as of
the date of this press release, and ViewRay assumes no obligation
to update the forward-looking statements, or to update the reasons
why actual results differ from those projected in the
forward-looking statements, except as required by law. Investors
should consult all of the information set forth herein and should
also refer to the risk factor disclosure set forth in the reports
and other documents ViewRay files with the SEC available at
www.sec.gov.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/viewray-partners-with-largest-independent-distributor-in-australia-and-new-zealand-to-bring-benefits-of-mri-guided-radiation-therapy-to-the-region-300833518.html
SOURCE ViewRay, Inc.; Device Technologies